Abstract No. 167: Survival Benefits of Yttrium-90 Radioembolization (SIR-Spheres) for Hepatic Metastasis from Melanoma: Preliminary Study

Dhanasekaran, Renumathy; Khanna, Vinit; Lawson, David H.; Delman, Keith A.; Kim, H.S.

doi:10.1016/j.jvir.2008.12.154

Cited by 6 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sir-Spheres have predominantly been used in liver metastases from colorectal cancer and in unresectable primary hepatocellular carcinomas, however there is also experience in patients with liver metastases from other primary tumors including both cutaneous and ocular melanomas. The outcomes of patients with ocular melanoma treated with Sir-Spheres, after either previous TACE or chemotherapy, are summarized in Table II [11][12][13]. Other reported series have included a small number of melanoma patients, such as Bester et al [14] and Sato et al [15] The extent of liver replacement by tumor, degree of liver dysfunction, performance status, and PET imaging results have been reported to predict response to therapy.…”

Section: Clinical Results Of Sir-spheres For Metastatic Melanomamentioning

confidence: 99%

Intra‐arterial infusion and chemo‐embolization for melanoma liver metastases

Lodh

Maher

Guminski

2014

Journal of Surgical Oncology

View full text Add to dashboard Cite

This article will review the rationale for hepatic arterial administration of agents to treat melanoma liver metastases, the techniques and practical considerations pertinent to hepatic arterial therapy, the variety of agents that have been used and the reported outcomes. Recent and emerging developments will be highlighted and the potential role of liver-directed therapies in the context of molecular advances and improved systemic therapy will be discussed.

show abstract

Section: Clinical Results Of Sir-spheres For Metastatic Melanomamentioning

confidence: 99%

Intra‐arterial infusion and chemo‐embolization for melanoma liver metastases

Lodh

Maher

Guminski

2014

Journal of Surgical Oncology

View full text Add to dashboard Cite

show abstract

“…Preliminary results of a study evaluating various liver-directed catheter therapies in patients with unresectable liver metastases from chemotherapy-refractory cutaneous or ocular melanoma reported better PFS (10.1 vs 2.30 months; P = .04) and OS (15.5 vs 5.9 months; P = .04) in those treated with yttrium-90 microspheres compared with standard transcathether ablation. 16 Patients with low-volume metastatic disease and absence of extrahepatic disease demonstrate greatest survival following yttrium-90 radioembolization treatment. 17 Of note, our study included patients with poor prognostic factors including 50% with an elevated LDH and relatively moderate liver disease burden.…”

Section: Discussionmentioning

confidence: 99%

A pilot study of intrahepatic yttrium‐90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver‐only metastases

et al. 2019

View full text Add to dashboard Cite

Background Metastatic uveal melanoma is a highly aggressive disease with no standard of care treatment option. A large proportion of patients have liver‐only metastatic disease which raises the question if liver‐directed therapy can be efficacious in this subpopulation. Aims The study aims to evaluate the safety and efficacy of radiosensitizing chemotherapy in combination with yttrium‐90 microspheres in patients with uveal melanoma with liver‐only metastases. Methods and results This single arm, open labeled, non‐randomized study enrolled 10 patients with liver‐only metastatic uveal melanoma between November 2012 and January 2018. Eligible patients received intrahepatic yttrium‐90 microspheres followed by intravenous cisplatin (20 mg/m2) for 5 days. Ten patients were enrolled, but nine patients received treatment who were included in the final analysis with a median follow‐up of 30 months (range 7 to 44). Five (50%) were female, five (50%) had an elevated lactate dehydrogenase (LDH), and one (10%) had prior anti‐PD‐1 therapy. The combination was well tolerated with no greater than or equal to grade 3 toxicity observed. The liver objective response rate (ORR) was 33% (3/9), the median progression‐free survival (PFS) in the liver was 3 months (95% CI, 3‐NA), and the extrahepatic PFS was 3 months (95% CI, 3‐NA). Seventy‐eight percent (7/9) received an immune checkpoint inhibitor on disease progression, with no responses seen. The median overall survival (OS) was 10 months (95% CI, 7‐NA). Conclusion The combination of cisplatin with yttrium‐90 microspheres was well tolerated; however, it was associated with intrahepatic disease control of relatively short duration. No responses were seen in patients treated with immune checkpoint inhibitors post radioembolization.

show abstract

“…Dhanasekaran et al reported 12 patients with melanoma, who failed systemic therapy and were treated with Y-90 radioembolization (SIR-Spheres) (14). Overall median survival from the diagnosis of liver metastases was 13.9 months (6.2–21.6).…”

Section: Radioembolization In Liver Metastases Other Than Mcrcmentioning

confidence: 99%

Beyond Hepatocellular Carcinoma and Colorectal Metastasis: The Expanding Applications of Radioembolization

Zurkiya

Ganguli

2014

Front. Oncol.

View full text Add to dashboard Cite

As a relatively safe outpatient procedure, radioembolization can potentially be used to treat any type of tumor within the liver, primary or metastatic. The safety and effectiveness of radioembolization in the treatment of hepatocellular carcinoma (HCC) and metastatic colorectal cancer (mCRC) has led many groups to explore its application in other malignancies. Moreover, other organs, such as the lungs and kidneys, have been explored as targets for therapy. Although the most data for radioembolization is related to HCC and mCRC, there is increasing experience and data regarding metastatic disease to the liver for other primary tumors. We review the current state of liver-directed therapy with radioembolization outside of HCC and mCRC, including metastatic neuroendocrine, breast, and melanoma, as well as limited experiences with other primary malignancies. Applications of radioembolization related to these other cancers and new trends and future directions will be discussed. With increasing use and availability of radioembolization, it promises to serve an expanding role in the repertoire of tools available for treating and managing oncologic disease.

show abstract

Abstract No. 167: Survival Benefits of Yttrium-90 Radioembolization (SIR-Spheres) for Hepatic Metastasis from Melanoma: Preliminary Study

Cited by 6 publications

References 0 publications

Intra‐arterial infusion and chemo‐embolization for melanoma liver metastases

Intra‐arterial infusion and chemo‐embolization for melanoma liver metastases

A pilot study of intrahepatic yttrium‐90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver‐only metastases

Beyond Hepatocellular Carcinoma and Colorectal Metastasis: The Expanding Applications of Radioembolization

Contact Info

Product

Resources

About